busulfan + gemcitabine + bendamustine

This is a combination chemotherapy regimen consisting of three small-molecule alkylating and antimetabolite agents—busulfan, gemcitabine, and bendamustine. Each drug has a distinct mechanism of action:\n- **Busulfan** is an alkyl sulfonate that acts as an alkylating agent, causing DNA cross-linking and subsequent cell death.\n- **Gemcitabine** is a nucleoside analog (antimetabolite) that inhibits DNA synthesis by incorporation into DNA strands during replication, leading to apoptosis.\n- **Bendamustine** is a bifunctional mechlorethamine derivative with both alkylating and antimetabolite properties; it forms covalent bonds with DNA resulting in intra- and inter-strand crosslinks.\n\nThis combination has been explored as part of high-dose conditioning regimens prior to autologous stem cell transplantation (ASCT) for hematologic malignancies such as non-Hodgkin lymphoma (NHL). The GBM regimen (gemcitabine, busulfan, melphalan or cyclophosphamide) has demonstrated efficacy comparable to standard BEAM/BEAC regimens in NHL patients undergoing ASCT. While the specific triplet "busulfan + gemcitabine + bendamustine" does not appear widely reported as a named protocol in major studies or guidelines, all three drugs are established components of multi-agent chemotherapy protocols for lymphoid malignancies[7][1][6].